• Home
  • Search Results
  • Chondroitin sulfate-E is a negative regulator of a pro-tumorigenic Wnt/beta-catenin-Collagen 1 axis in breast cancer cells.

Chondroitin sulfate-E is a negative regulator of a pro-tumorigenic Wnt/beta-catenin-Collagen 1 axis in breast cancer cells.

PloS one (2014-08-05)
Catherine M Willis, Michael Klüppel
ABSTRACT

Expression of the glycosaminoglycan chondroitin sulfate-E (CS-E) is misregulated in many human cancers, including breast cancer. Cell-surface associated CS-E has been shown to have pro-tumorigenic functions, and pharmacological treatment with exogenous CS-E has been proposed to interfere with tumor progression mediated by endogenous CS-E. However, the effects of exogenous CS-E on breast cancer cell behavior, and the molecular mechanisms deployed by CS-E are not well understood. We show here that treatment with CS-E, but not other chondroitin forms, could interfere with the invasive protrusion formation and migration of breast cancer cells in three-dimensional organotypic cultures. Microarray analysis identified transcriptional programs controlled by CS-E in these cells. Importantly, negative regulation of the pro-metastatic extracellular matrix gene Col1a1 was required for the anti-migratory effects of exogenous CS-E. Knock-down of Col1a1 gene expression mimics the effects of CS-E treatment, while exposing cells to a preformed collagen I matrix interfered with the anti-migratory effects of CS-E. In addition, CS-E specifically interfered with Wnt/beta-catenin signaling, a known pro-tumorigenic pathway. Lastly, we demonstrate that Col1a1 is a positively regulated target gene of the Wnt/beta-catenin pathway in breast cancer cells. Together, our data identify treatment with exogenous CS-E as negative regulatory mechanism of breast cancer cell motility through interference with a pro-tumorigenic Wnt/beta-catenin-Collagen I axis.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Fluorescein, for fluorescence, free acid
Sigma-Aldrich
Anti-β-Catenin antibody produced in rabbit, whole antiserum
Sigma-Aldrich
Monoclonal Anti-β-Catenin antibody produced in mouse, clone 15B8, ascites fluid
Fluorescein, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Anti-CTNNB1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-LRP6 antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Anti-LRP6 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-CTNNB1 (Ab-33) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-CTNNB1 (Ab-37) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-CTNNB1 (Ab-654) antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-CTNNB1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab2
Sigma-Aldrich
Anti-LRP6 (center) antibody produced in rabbit, saturated ammonium sulfate (SAS) precipitated, buffered aqueous solution
Sigma-Aldrich
Anti-LRP6 (N-term) antibody produced in rabbit, saturated ammonium sulfate (SAS) precipitated, buffered aqueous solution
Sigma-Aldrich
Anti-CTNNB1 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-CTNNB1 antibody produced in mouse, clone 1C9, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Monoclonal Anti-β-Catenin antibody produced in mouse, clone 6F9, ascites fluid
Sigma-Aldrich
Rabbit anti-Beta-catenin Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.
Sigma-Aldrich
MISSION® esiRNA, targeting human COL1A1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Col1a1

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.